Blood Targets of Adjuvant Drugs Against COVID19

References

• Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for CoronavirusDisease 2019 (COVID-19). Review Jama. 2020. doi:10.1001/jama.2020.6019
   Web of Science ®Google Scholar
• Some drugs for COVID-19. Med Lett Drugs Ther. 2020;62(1595):49‐50.
   Google Scholar
• Li X, Zhang C, Liu L, Gu M. Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. FASEB J. 2020;34(5):6008‐6016.
   Web of Science ®Google Scholar
• McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859. doi:10.1016/j.phrs.2020.10485932360480
   PubMed Web of Science ®Google Scholar
• Lai MM, Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res. 1997;48:1–100.9233431
   PubMed Web of Science ®Google Scholar
• Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn. 2020;1‐10.
   Web of Science ®Google Scholar
• Pant S, Singh M, Ravichandiran V, Murty USN, Srivastava HK. Peptide-like and small-molecule inhibitors against Covid-19 [published online ahead of print, 2020 May 6]. J Biomol Struct Dyn. 2020;1‐10.
   Web of Science ®Google Scholar
• Liu X, Li Z, Liu S, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B. 2020. doi:10.1016/j.apsb.2020.04.008
   Web of Science ®Google Scholar
• Wei J, Zhang Y, Li D, et al. Integrating network pharmacology and component analysis study on anti-atherosclerotic mechanisms of total flavonoids of engelhardiaroxburghiana leaves in mice. Chem Biodivers. 2020;17(3):e1900629. doi:10.1002/cbdv.20190062931943763
   PubMed Web of Science ®Google Scholar
• Jo S, Kim H, Kim S, Shin DH, Kim MS. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Chem Biol Drug Des. 2019;94(6):2023–2030. doi:10.1111/cbdd.1360431436895
   PubMed Web of Science ®Google Scholar
• Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem. 2020;35(1):145–151. doi:10.1080/14756366.2019.169048031724441
   PubMed Web of Science ®Google Scholar
• Guo H, de Vries E, McBride R, et al. Highly pathogenic influenza a (h5nx) viruses with altered h5 receptor-binding specificity. Emerg Infect Dis. 2017;23(2):220–231. doi:10.3201/eid2302.16107227869615
   PubMed Web of Science ®Google Scholar
• Gao F, Ou HY, Chen LL, Zheng WX, Zhang CT. Prediction of proteinase cleavage sites in polyproteins of coronaviruses and its applications in analyzing SARS-CoV genomes. FEBS Lett. 2003;553:451–456. doi:10.1016/S0014-5793(03)01091-314572668
   PubMed Web of Science ®Google Scholar
• Gallant DM, Bishop MP. Cinanserin (SQ. 10,643): a preliminary evaluation in chronic schizophrenic patients. Curr Ther Res Clin Exp. 1968;10:461–463.4971651
   PubMed Web of Science ®Google Scholar
• Lang J, Yang N, Deng J, et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One. 2011;6(8):e23710.hh. doi:10.1371/journal.pone.0023710
   Web of Science ®Google Scholar
• Madu IG, Chu VC, Lee H, Regan AD, Bauman BE, Whittaker GR. Heparan sulfate is a selective attachment factor for the avian coronavirus infectious bronchitis virus Beaudette. Avian Dis. 2007;51(1):45–51. doi:10.1637/0005-2086(2007)051[0045:HSIASA]2.0.CO;217461266
   PubMed Web of Science ®Google Scholar
• Milewska A, Nowak P, Owczarek K, et al. Entry of Human Coronavirus NL63 into the Cell. J Virol. 2018;92(3):e01933–17. doi:10.1128/JVI.01933-1729142129
   PubMed Web of Science ®Google Scholar
• Ghiselli G. Heparin binding proteins as therapeutic target: an historical account and current trends. Medicines. 2019;6(3):E80. doi:10.3390/medicines603008031362364
   PubMedGoogle Scholar
• Buczek-Thomas JA, Rich CB, Nugent MA. Hypoxia induced heparan sulfate primes the extracellular matrix for endothelial cell recruitment by facilitating VEGF-Fibronectin interactions. Int J Mol Sci. 2019;20(20):E5065. doi:10.3390/ijms2020506531614727
   PubMed Web of Science ®Google Scholar
• Di Micco P, Russo V, Carannante N, et al. Clotting factors in COVID-19: epidemiological association and prognostic values in different clinical presentations in an Italian cohort. J Clin Med. 2020;9(5):E1371. doi:10.3390/jcm905137132392741
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. 2020 Lancet. 395. in press.
   Web of Science ®Google Scholar
• WHO. Clinical management of severe acute respiratory infection Wuhan novel coronavirus (2019-nCoV) infection is suspected. Interim guidance. 28 January 2020. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed 619, 2020.
   Google Scholar
• Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004;383((pt 1)):45–51. doi:10.1042/BJ2004063415283675
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879. doi:10.1038/nm126716007097
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14‐20. doi:10.1016/j.ejim.2020.04.037
   Web of Science ®Google Scholar
• Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75(6):1382‐1385. doi:10.1161/HYPERTENSIONAHA.120.15082
   Web of Science ®Google Scholar
• Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? JAMA. 2020. in press. doi:10.1001/jama.2020.4812
   Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020. in press. doi:10.1001/jamacardio.2020.1017
   Web of Science ®Google Scholar
• Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc. (Bayl Univ Med Cent) 2018;31(4):419–423. doi:10.1080/08998280.2018.1499293
   Google Scholar
• Hyman DA, Siebert VR, Birnbaum GD, Alam M, Birnbaum YA. Modern history RAAS inhibition and beta blockade for heart failure to underscore the non-equivalency of ACEIs and ARBs.. Cardiovasc Drugs Ther.2020;34:215–221. in press. doi:10.1007/s10557-020-06950-w32219664
   PubMed Web of Science ®Google Scholar
• Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020. in press. doi:10.1002/ddr.21656
   Web of Science ®Google Scholar
• Wan J, Sun W, Li X, et al. Inflammation inhibitors were remarkably up-regulated in plasma of severe acute respiratory syndrome patients at progressive phase. Proteomics. 2006;6(9):2886–2894. doi:10.1002/pmic.20050063816649161
   PubMed Web of Science ®Google Scholar
• Acanfora D, Ciccone MM, Scicchitano P, Acanfora C, Casucci G. Sacubitril/valsartan in COVID-19 patients: the need for trials. Eur Heart J Cardiovasc Pharmacother. 2020;pvaa044. doi:10.1093/ehjcvp/pvaa04432369103
   PubMed Web of Science ®Google Scholar
• Pedersen SF, Ho YC. SARS-CoV-2: A storm is raging. J Clin Invest. 2020;137647.32217834
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020;137244.32217835
   PubMed Web of Science ®Google Scholar
• Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020;12:269–273. in press. doi:10.2217/imt-2020-006732212881
   PubMed Web of Science ®Google Scholar
• Bennardo F, Buffone C, Giudice A. New therapeutic opportunities for COVID-19 patients with Tocilizumab: possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws. Oral Oncol.2020;106:104659. in press. doi:10.1016/j.oraloncology.2020.10465932209313
   PubMed Web of Science ®Google Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):in press.
   Web of Science ®Google Scholar
• Mahase E. Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ. 2020;368:m641. doi:10.1136/bmj.m64132071063
   PubMed Web of Science ®Google Scholar
• Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect. 2020;9(1):558–570. doi:10.1080/22221751.2020.173664432172672
   PubMed Web of Science ®Google Scholar
• Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64:in press. doi:10.1128/AAC.00399-20
   Web of Science ®Google Scholar
• Yamazaki-Nakashimada MA, Unzueta A, BereniseGámez-González L, González-Saldaña N, Sorensen RU. BCG: a vaccine with multiple faces. Hum Vaccin Immunother. 2020;1‐10.
   Web of Science ®Google Scholar
• Redelman-Sidi G. Could BCG be used to protect against COVID-19? Nat Rev Urol. 2020;17(6):316‐317. doi:10.1038/s41585-020-0325-9
   Web of Science ®Google Scholar